SGLT-2 inhibitors, which have obtained indications for chronic kidney disease, are emerging as the mainstay of chronic disease management along with diabetes. According to data from the Korean Diabetes Association, the rate of kidney disease accompanied by type 2 diabetes patients in Korea was about 30%, and one in three diabetes patients in Korea had renal function abnormalities. Studies have also shown that diabetes (40%) is the most common cause of end-stage kidney disease. Diabetes patients have an average annual glomerular filtration rate (eGFR) decrease about twice as quickly as those without diabetes, and the 10-year neoplasia rate for diabetic patients is very low at 40%.

Effectiveness of SG

Eo, Yun-Ho(unkindfish@dailypharm.com)